TOI Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 12.68%, SMA50 -7.12%, SMA200 -10.53%). The stock’s 14-day RSI is 54.88 (neutral), while the ATR of 0.22 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -38.93% below its high and over 395.43% above its low. Average 10-day trading volume of 1.21 million shares is below the 3-month average of 1.75 million, indicating normal recent market interest.

The Oncology Institute, Inc. has 93.50 million shares outstanding. The public float is 77.56 million shares, elevated short interest at 7.61% of float. This equals 5.83 million shares. The short ratio is 3.22 days. Institutional investors hold 56.37% of the float. Insiders own 20.14%. TOI HC I, LLC holds 14.42 million shares, Chernett Jorey has 10.50 million shares and Hively Brad has 683.72 thousand shares. Over the past six months, insider transactions show net buying. They sold 155.93 thousand shares across 5 transactions.

The Oncology Institute, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.47. This means the shares are trading below this model’s fair value.

Wall Street analysts project EPS growth of 51.7% annually over the next five years. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.09. Next year's EPS is expected at $19.61. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $8.00 to $5.00. The high target offers 96.56% upside. The low target suggests 22.85% downside. The mean target is $6.14. This offers 50.86% upside. The Oncology Institute, Inc. earnings surprise history is a mixed track record. The quarter that ended March 12, 2026, missed forecasts by -25.0%. The prior quarter beat by -85.89%. Over the last six quarters, Apple has recorded several small beats. These include 70.0% in August 13, 2024.

The Oncology Institute, Inc. (NASDAQ:TOI) closed at $4.07 USD, gaining $0.27 (7.11%) from the previous close of $3.80. The stock is currently mid-range between its 52-week high and low $2.02 and $4.88. With a market capitalization of about $402.28 million, The Oncology Institute, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.36). Key stats such as the average daily volume over the past year has been around 1.73 million shares, in line with its 52-week average. Headquartered in Cerritos, CA, The Oncology Institute, Inc. operates in the Healthcare sector and the Medical - Care Facilities industry. Led by CEO Daniel Virnich, the company employs approximately 825 people and listed since June 04, 2020. The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States.

The Oncology Institute, Inc. trades at a P/E ratio of -66.11, slightly below the S&P 500 average, with a price-to-sales ratio of 0.78 and a price-to-book ratio of -254.88 indicating negative book value, which may reflect financial stress. The P/FCF stands at -14.05, also below market averages.

The Oncology Institute, Inc. (NASDAQ:TOI) shares are flat -3.37% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows The Oncology Institute, Inc. trading at a premium to the broader market with a P/E of -66.11. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.92, suggesting 45.45% upside. Our AI forecast model points to short-term weakness (-0.74% over two weeks), a medium-term fall (-11.3% over three months), and a longer-term gain (210.32% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that The Oncology Institute, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.74%, with price expected at $4.04 by May 20, 2026, within a range of $3.74 to $4.36 3-Month Outlook: Projected fall of -11.3%, reaching $3.61 by August 04, 2026, with a range of $3.54 to $3.71. 1-Year Outlook: Projected gain of 210.32%, with price at $12.63 by May 06, 2027, within a range of $12.57 to $12.70.